News & Updates
Filter by Specialty:
Infusion-to-injection infliximab switch safe, helps lower risk of IBD relapse for some patients
Switching from intravenous to subcutaneous infliximab appears to be safe and well-accepted, resulting in a reduced risk of relapse in some inflammatory bowel disease (IBD) patients, according to data from the REMSWITCH study.
Infusion-to-injection infliximab switch safe, helps lower risk of IBD relapse for some patients
24 Aug 2022
OASIS-1: Thumbs up for mirikizumab in moderate-to-severe plaque psoriasis
The interleukin (IL)-23 inhibitor mirikizumab demonstrates superior efficacy in the treatment of patients with moderate-to-severe plaque psoriasis as compared with placebo, with initial responses during induction preserved through the maintenance phase, according to the results of the phase III OASIS-1 trial.
OASIS-1: Thumbs up for mirikizumab in moderate-to-severe plaque psoriasis
23 Aug 2022
FLT3 inhibitor improves survival in patients with FLT3+ acute myeloid leukaemia
Patients diagnosed with acute myeloid leukaemia with an FLT3 mutation (FLT3+ AML) may benefit from the addition of an FLT3 inhibitor to intensive chemotherapy postinduction by improving event-free (EFS) or overall survival (OS), suggests a study.
FLT3 inhibitor improves survival in patients with FLT3+ acute myeloid leukaemia
23 Aug 2022
Patient decision aid helps in decision-making process when selecting regimen for CRC
A newly developed patient decision aid (PDA) aids in the shared decision-making in choosing first-line targeted therapy for metastatic colorectal cancer (CRC), reports a study in Taiwan.
